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Abstract
Objectives: An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This
vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated
bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.
Design: Double-blind, randomized, placebo controlled trial
Setting: The trial was conducted in the clinical trial ward of the Infectious Diseases Hospital in Kolkata, India
Participants: The participants were 101 healthy adults (males and non-pregnant females) aged 18–40 years and 100 healthy
children (males and non-pregnant females) aged 1–17 years.
Interventions: Participants were randomized to receive either the bivalent killed whole cell oral cholera vaccine or placebo
(killed oral Escherichia coli K12)
Outcome Measures: For safety: proportion of subjects with adverse events during the duration of study participation. For
immunogenicity: Proportion of subjects who had a $4-fold rise in serum vibriocidal antibody titers 14 days after the second
dose of vaccine or placebo.
Results: Adverse reactions were observed with similar frequency among vaccine and placebo recipients in both age groups.
Among adults 4% of vaccine and 8% of placebo recipients and among children 4% of vaccine and 2% of placebo recipients
had at least one adverse event within 28 days of the first dose of the vaccine. Following immunization, 53% of adult and
80% of children vaccinees showed a $4 fold rise in serum V. cholerae O1 vibriocidal antibody titers. A less pronounced
response to V. cholerae O139 vibriocidal antibody titers post-immunization was noted among vaccinees.
Conclusions: We found the vaccine to be safe and immunogenic in a cholera-endemic area in India.
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Introduction
The World Health Organization (WHO) advocates the use of
oral cholera vaccines in the control of cholera in addition to other
control measures [1]. Only one internationally licensed oral
cholera vaccine is available but this remains prohibitively
expensive for routine use in cholera-endemic countries. Vietnam
produces a two-dose, oral killed whole cell cholera vaccine that has
been given through its public health system and is currently
produced at about US$0.40 per dose. This bivalent (Vibrio cholerae
01 and 0139) vaccine and its monovalent (O1) predecessor have
been found to be safe and to confer significant protection against
El Tor cholera in both children and adults [2–4]. Since 1997,
more than 9 million doses of this bivalent vaccine have been
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2323administered in Vietnam. No serious adverse events have been
associated with this vaccine [5].
In order to expand the use of the oral cholera vaccine globally,
the Diseases of the Most Impoverished (DOMI) Programme of the
International Vaccine Institute (IVI) decided to support reformu-
lation of the vaccine to comply with WHO standards. The
reformulated vaccine was shown to be safe and immunogenic
among Vietnamese adults [6]. Prior to technology transfer to a
developing country producer outside Vietnam, we assessed the
safety and immunogenicity of this reformulated vaccine in a
cholera endemic area in Kolkata, India.
Methods
Participants
The study was conducted in the clinical trial ward of the
Infectious Diseases Hospital in Kolkata, India. The trial protocol
was approved by the of the Ethics Committee of the National
Institute of Cholera and Enteric Diseases (NICED), the Health
Ministry Screening Committee of India and the Institutional
Review Board of the IVI in Seoul. The study was monitored by an
independent Data Safety and Monitoring Board (DSMB) who
reviewed the safety data among adults before proceeding to
recruitment of children. We recruited healthy adults (males and
non-pregnant females) aged 18–40 years followed by healthy
children (males and non-pregnant females) aged 1–17 years.
Written informed consent was obtained prior to enrolment and
written assent was also obtained from children 12–17 years.
Individuals who were pregnant, with abdominal pain, vomiting,
loss of appetite, generalized ill-feeling or nausea during the
preceding 24 hours; or diarrhea or history of anti-diarrheal or
antibiotic use during the past week; or history of diarrhea and
abdominal pain lasting for more than 2 weeks during the past
6 months were excluded.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Interventions
Participants were randomized to receive either 2 doses of the
vaccine or placebo, given 14 days apart. Each dose of the vaccine
contained 600 ELISA Units (EU) of lipopolysaccharide (LPS) of
formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973);
300 EU LPS of heat-killed V. cholerae Ogawa classical biotype
(Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa
classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae
Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin-
killed V. cholerae O139 (4260B). The vaccine had no detectable
cholera toxin (1 ng/ml detection limit). The LPS and toxin assays
were performed at the University of Gothenburg. All other lot
release assays were performed at the Company for Vaccine and
Biological Production No. 1 in Hanoi and Shantha Biotechnics in
Hyderabad.
The placebo consisted of heat-killed Escherichia coli K12 and
was identical in appearance to the vaccine. Non-specific LPS
content was not measured in the placebo, but this strain has
been used in previous oral cholera vaccine clinical trials [3,6,7].
Both placebo and vaccine were packaged as liquid formulations
in identical vials containing five 1.5-ml doses and were stored
at 4–8uC before administration. The vaccine or placebo was
given in two doses separated by a two week interval and
administered by oral syringe without a needle after which each
participant was offered a glass of water. No buffer was co-
administered.
Objectives
We investigated whether the reformulated killed oral cholera
vaccine was safe and immunogenic among adults and children
residing in a cholera-endemic area.
Outcomes
The primary endpoints of the study were as follows: for safety, the
proportion of subjects with diarrheal adverse events during the study
period and for immunogenicity,the proportion of subjects exhibiting
4-fold or greater rises in titers of serum vibriocidal antibodies relative
to baseline, 14 days after the second dose of either the killed oral
cholera vaccine or placebo. Additional analyses were performed to
compare all adverse events during the study period as well as
geometric mean serumvibriocidal titersat baseline and 14 days after
dose 2 among vaccine and placebo recipients.
Participants were enrolled in the clinical trial ward of the
Infectious Diseases Hospital in Kolkata. Adverse events were
solicited for 3 days after the first dose. Two weeks after the first
dose was given, subjects returned to the clinic for the second dose
and were asked to follow-up daily for 3 days. During each follow-up
day, study physicians conducted a structured interview regarding the
participants’over-alllevelofactivityand bowelmovementsaswellas
occurrence of symptoms such as diarrhea, abdominal pain, loss of
appetite, nausea, general ill feeling, fever, headache or vomiting
during the previous 24 hours. For young children, parents or
caretakers were interviewed. Diarrhea was defined as 3 or more
loose or liquid stools in a 24 hour period. Two weeks after each dose
was given, subjects were asked about any illness that may have
occurred,and treatmentreceived,duringthe interval period.Serious
adverse events (SAEs) were defined as any medical events which
were incapacitating or preventing normal activities and included
death, life-threatening events, hospitalization, and disability.
Blood samples were obtained prior to the first dose and 14 days
after the second dose. Sera were separated, shipped frozen and
stored at 270uC until paired testing was performed. The microtiter
technique was used to detect serum vibriocidal antibodies to V.
cholerae O1 El Tor Inaba strain (T19479) at the IVI in Seoul as
previously described [8]. For the serum vibriocidal antibodies to V.
cholerae O139, a modified microtiter assay was performed at the
University of Gothenburg as previously described [9] using a
spontaneously streptomycin-resistant variant derived from the
capsule-deficient CIRS134 [[10] (concentration 2610
5 )a si n d i c a t o r
strain. Two-fold serial dilutions of pre- and post vaccination sera
were performed in duplicates, and the mean of the two
determinations was the final titer. The assay was repeated if a $2-
fold difference was noted between the results of the duplicate tests.
Testing was performed by technicians blinded to the study agent
received by the subjects. Initial serum dilutions for testing were 1:2.5
for V. cholerae O1 and 1:10 for V. cholerae O139, respectively.
Vibriocidaltiters,2.5for V.choleraeO1and,10forV.choleraeO139
were considered as 1.25 and 5, respectively, for statistical analyses.
‘‘Seroconversion’’ was defined as a four-fold or greater increase in
titer between pre-vaccination and post-vaccination sera.
Sample size
The ‘‘non-inferiority’’ approach using a 1 –sided 95%
confidence interval was used to calculate the sample size since
this allowed us to rule out clinically unacceptable high rates of
diarrheal adverse event occurring during the 3 days after either
dose as well as establish that the vaccine induced adequate
seroconversion to V. cholerae O1 Inaba among recipients [11].
Assuming a 10% diarrheal rate among placebo and vaccine
recipients alike, to exclude a vaccine-placebo difference in the rate
of diarrhea of greater than 20% (upper boundary of the 1-tailed
Oral Cholera Vaccine
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number of subjects required for each group was 39. For serum
vibriocidal responses, assuming a background rate of 5%
seroconversion among placebo recipients after the second dose
and a true vibriocidal response in the vaccine group of 60%, to
exclude a vaccine-placebo difference of 30% (lower boundary of
the 1-tailed 95% confidence interval) with a power of 0.9, the
minimum of subjects required for each group was 40. To adjust for
the number of persons expected to drop out of the study, at least
50 persons were therefore required in each group.
Randomization –Sequence generation
Separate randomization lists for adults and children were prepared
by a statistician in IVI who was otherwise not involved in the study.
Randomization numbers were generated in blocks of 8 using the
program Visual Fortran 5.0. (Digital, USA) For the children’s study,
to ensure that each age group was represented, approximately 33–34
children of each age group (1 to 5 years, 6 to 10 years and 11 to
17 years) were randomized to receive either vaccine or placebo.
Randomization – Allocation Concealment
Study agents were coded using 8 letters (4 for vaccine and 4 for
placebo) in the adult trial and 8 different letters in the pediatric trial.
Only the code letters on the vials identified the study agents as
vaccine or placebo. The codes were revealed to the researchers once
recruitment, data collection, and laboratory analyses were complete.
Randomization – Implementation
The agent administered was determined according to the
randomization list. The study nurse or medical officer randomized
the participants according to the next available number on entry
into the trial. The randomization numbers were linked to one of
the 8 letter codes for the adult study and one of the 8 letter codes
for the children’s study.
Blinding
The vials were labeled by letter codes at Shantha Biotechnics in
Hyderabad according to the list prepared by the statistician at IVI.
All study personnel and participants were blinded to treatment
assignment during the duration of the study.
Statistical Methods
Data was entered in Visual Fox Pro
TM v 7.0 (Microsoft
Corp, USA) and analyses were performed using Stata
TM v 9.0
(Stata Corp., USA). Analyses for contrasts of dichotomous
outcomes such as adverse events and seroconversion were
performed with the chi-square test, except when data was sparse
for which Fisher’s exact test was used. For contrasts of
vibriocidal titers, Student’s t-test was performed. Serum
vibriocidal titers and fold rises were logarithmically transformed
prior to statistical analyses.
To assess vaccine versus placebo geometric mean fold rises in
serum antibody titers, after controlling for potentially confounding
variables, multiple linear regression models were fitted. In the
models, the logarithm of the serum vibriocidal titer at the post-
vaccination bleed was the dependent variable, and vaccination
status (vaccine versus placebo), together with the logarithm of the
titer of baseline serum vibriocidal antibodies and other potentially
confounding variables were fitted as independent variables. In
these models we exponentiated the coefficient for the vaccination
variable to estimate the ratio of geometric mean-fold rise of serum
antibodies in vaccinees to rises in placebo-recipients, after
controlling for the potentially confounding variables in the models.
Standard errors of the coefficients were used to estimate P values
and 95% confidence intervals.
Contrasts of the primary outcomes, diarrhea following dosing
and serum vibriocidal seroconversion, were evaluated with 1-tailed
P values and 1-tailed 95% confidence intervals. Statistical
evaluations of all other comparisons were 2-tailed.
Figure 1. Flowchart of adult and children participants in the study.
doi:10.1371/journal.pone.0002323.g001
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Participant Flow and Recruitment
The flow of subjects in the adults and children trials is shown
in Figure 1. Adult participants were recruited from August to
September 2005 and children were recruited from September to
October 2005. We enrolled 101 adults who received at least one
dose of either vaccine or placebo. On review after the first
dose, 1 participant was found to be ineligible because he was
17 years of age at enrollment. Of the 100 eligible adults, all (51
vaccinees and 49 placebo recipients) received the assigned two
dose regimen and were followed up with a second blood
collection. Subsequently, 100 children were enrolled, of whom
49 received 2 doses of vaccine and 49 received 2 doses of
placebo. One child participant randomized to receive vaccine
was given placebo for the second dose and one child participant
randomized to receive placebo was given vaccine for the
second dose. All children were able to completely swallow the
study agent dose and were followed up with a second blood
collection.
Baseline Data
Table 1 shows the characteristics of subjects in the vaccine and
placebo groups. The mean age of adult vaccinees was 26.8 years
(range 18–40) compared to 27.5 years (range 18–40) among
placebo recipients. The mean age of children vaccinees was
8 years (range 1–16) compared to 8.5 years (range 1–16) of
placebo recipients.
Table 1. Characteristics of adult and children vaccine and
placebo recipients
Adults Children
Characteristics Vaccine Placebo Vaccine Placebo
n=51 n=50 n=50 n=50
Age
Mean (SD) 26.8 (6.9) 27.5 (7.2) 8.0 (4.3) 8.5 (5.1)
Median 25 27 7.5 8
Sex
Male 25 (49%) 24 (48%) 31 (62%) 21 (42%)
doi:10.1371/journal.pone.0002323.t001
Table 2. Comparison of solicited adverse events among adults and children following receipt of the first and second doses of
vaccine and placebo
Adults Children
Vaccine N (%) Placebo N (%) P Value Vaccine N (%) Placebo N (%) P Value
Within 3 days after the first dose N=50 N=51 N=50 N=50
Diarrhea 1 [18%]
a 0 1 [9%] 0
Abdominal Pain 1 1 0 0
Loss of appetite 1 0 0 0
Nausea 1 1 0 0
Vomiting 2 1 1 2
Fever 0 0 1 0
Headache 0 0 0 0
General ill feeling 1 0 0 0
Within 3 days after the second dose
Diarrhea 0 0 0 0
Abdominal Pain 0 0 0 0
Loss of appetite 0 0 0 0
Nausea 0 0 0 0
Vomiting 0 0 0 0
Fever 0 2 0 0
Headache 0 1 0 0
General ill feeling 0 0 0 0
No (%) with $ one adverse event within
3 days of the first dose
2( 4 )
b 2 (4) 1 2 (4) 2 (4) 1
No (%) with $ one adverse event within
3 days of the second dose
0 (0) 2 (4) .50 0 (0) 0 (0) 1
No (%) with $ one adverse event within
28 days of the first dose
2 (4) 4 (8) .68 2 (4) 1 (2) .56
No (%) with a serious adverse event within
28 days of the first dose
1 (2) 0 (0) .50 2 (4) 1 (2) .56
aValues in brackets represent the upper boundaries for one tailed 95% confidence interval for the differences in the diarrheal adverse events among vaccinees
compared to placebo recipients
bValues in parenthesis represent the percentage of group total
doi:10.1371/journal.pone.0002323.t002
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For safety, intention-to-vaccinate analysis was performed which
included all subjects randomized in the study who received one or
more dose of any study agent. 101 adults and 100 children were
included in this analysis. For immunogenicity, per-protocol
analysis was performed on randomized, eligible subjects who
received 2 doses of the correct study agent and were available until
the last follow-up. 100 adults were included for analysis of
seroconversion to V. cholerae O1 and V. cholerae O139. For children,
98 were included for analysis of seroconversion to V. cholerae O1
but due to small amounts of sera, only 88 sera were available for
testing to V. cholerae O139.
Outcomes
No adverse event occurred more frequently in the vaccine than in
the placebo group (Table 2). There were 4 serious adverse events
(SAE) in 2 vaccinees (1 child, 1 adult) and 2 placebo recipients (both
children) who were hospitalized for vomiting and dehydration. All
four had eaten a local fermented rice preparation a few hours prior
to the onset of vomiting. All other adverse events were mild. The
95% one-sided confidence intervals for the occurrence of diarrheal
events excluded more than a 19% greater occurrence among adult
vaccinees and more than an 18% greater occurrence among
children vaccinees than in placebo recipients in each age group.
There were statistically significant differences in the baseline
geometric mean titers (GMT) of vibriocidal antibodies to V. cholerae
O1 Inaba between adults and children, (P=,0.01) with titers
being lower in children (Table 3). The baseline vibriocidal
antibody titer to V. cholerae O1 Inaba ranged from ,2.5 to 5120
in adults and ,2.5 to 1280 in children. There were no statistically
significant differences in the baseline geometric mean vibriocidal
antibody titers to V. cholerae O139 between the two age groups,
(P=0.098). Baseline vibriocidal antibodies to V. cholerae O139
ranged from 5 to 7650 in adults and 5 to 3200 in children.
Table 3 shows that the differences in the geometric mean fold
(GMF) rises of V. cholerae O1 Inaba vibriocidal antibody titers
among vaccinees versus placebo recipients in both adults and
children were statistically significant. Multiple linear regression
models adjusting for baseline titers revealed similar findings and
remained statistically significant (P,.01). Among vaccinees, there
was a 4.5 fold rise among adults, and among children there was a
12.3 fold rise. Over-all, there was a 7.4 fold-rise, 14 days after
receipt of the second dose.
Seroconversion rates were higher for vaccinees than for placebo
recipients in both adults (53% vs. 0%; P,.01) and children (80%
vs. 2%; P,.01). The 95% confidence intervals for differences in
seroconversion rates between vaccine and placebo recipients
excluded a 36% or lower response rate in adults and 60% or lower
response rate in children.
Although seroresponses to V. cholerae 01 were higher in children
than in adults, it was noteworthy that among adult vaccinees with
baseline titers #80, 11 (85%) seroconverted and a 19- fold rise in
serum antibodies from baseline was noted. Similarly, among
children vaccinees with such low baseline titers, 29 (85%)
seroconverted, and a 23-fold rise in serum antibodies from
baseline was observed (see Table 4). Correspondingly, multivar-
iable models demonstrated that differences between vaccinees and
placebo recipients in geometric mean-fold rises in serum
vibriocidal antibodies and in rates of seroresponses were inversely
related to baseline serum vibriocidal titers.
Table 3. Serum vibriocidal antibody titers to V. cholerae O1 Inaba and V. cholerae O139 at baseline and 14 days after the second
dose among subjects with paired blood specimens
V. cholerae O1 V. cholerae O139
Adults
Vaccine recipients
n=49
Placebo recipients
n=51 P value
Vaccine recipients
n=49
Placebo recipients
n=51 P value
GMT
a
Bleed 1 251.6 143.5 0.13 189.4 201.6 0.79
Bleed 2 1127 164.4 ,0.01 307.5 234.3 0.16
GMF-rise
b (95% CI) 4.5 (3.1, 6.5) 1.1 (1.1, 1.3) 0.04 1.6 (1.4, 2.0) 1.2 (1.0, 1.4) ,0.01
No. of subjects who
seroconverted
c
26 (53%) 0 ,0.01 5 (10%) 1 (2%) 0.11
95% CI lower boundary
d 36% –
Children Vaccine recipients
n=49
Placebo recipients
n=49
P value Vaccine recipients
n=45
Placebo recipients
n=43
P value
GMT
a
Bleed 1 32.4 23.7 0.48 116.9 126.6 0.78
Bleed 2 407 25.1 ,0.01 291.1 151.7 ,0.01
GMF-rise
b (95% CI) 12.6 (7.4, 21.3) 1.1 (1.0, 1.2) ,0.01 2.5 (1.9, 3.3) 1.2 (1.1, 1.4) ,0.01
No. of subjects who
seroconverted
c
39 (80%) 1 (2%) ,0.01 12 (27%) 1 (2%) ,0.01
95% CI lower boundary
d 60% –
aGeometric mean reciprocal titer for the cited bleed
bGeometric mean-fold rise between first and second bleed.
cNumber of subjects with $4 fold rise in titers between first and second bleed
dLower boundary of the one-tailed, 95% confidence intervals for the percentage of vaccinees that seroconverted compared to the placebo recipients (shown because
the primary hypotheses for the trial included this lower boundary, see text).
doi:10.1371/journal.pone.0002323.t003
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V. cholerae O139 in vaccinees compared to placebo recipients in
both adults and children (Table 3) were less pronounced compared
to the responses seen to O1 Inaba, although these were statistically
significant (P,.01). Multiple linear regression models adjusting for
baseline titers revealed that among vaccinees, there was a 1.4 fold
rise among adults, a 2 fold rise among children and a 1.6 fold rise
overall in vibriocidal titers to O139, 14 days after receipt of the
second dose. These findings were statistically significant (P,.01).
However, the rates for seroconversion between vaccinees and
placebo recipients were only different significantly in children
(P,.01).
Discussion
This is the first study to show that a 2-dose regimen of a recently
reformulated Vietnamese oral killed whole cell cholera vaccine is
safe, well-tolerated, and immunogenic in a cholera-endemic area.
It is interesting to compare serum anti-O1 Inaba vibriocidal
antibody responses to this vaccine in this study with those observed
in an earlier study of an identical regimen of this vaccine in SonLa,
Vietnam, where cholera is not endemic [6]. Overall geometric
mean-fold rises in serum antibodies were lower in Kolkata (4.5-
fold in adults and 12.6-fold in children) than in SonLa (26.8-fold)
where only adults were studied. It was noteworthy, however, that
higher baseline antibody titers were noted in Kolkata than in
SonLa. Indeed, among subjects in Kolkata with low baseline titers
(#80), a 19-fold rise from baseline was noted in adults and a 23-
fold rise from baseline was seen in children. These observations,
together with the analyses in the present study showing that
responses to the vaccine were inversely related to baseline serum
vibriocidal antibody titer, suggest that the higher pre-existing
vibriocidal antibody titers in Kolkata than in SonLa explained the
lower overall responses seen in the present study [7,12,13].
A previous trial found similar serum vibriocidal responses to V.
cholerae O1 Inaba induced by 2 dose regimens of the internation-
ally licensed, oral B subunit killed whole cell vaccine and the
previous version of the Vietnamese oral killed whole cell vaccine
[3]. The responses to the reformulated vaccine evaluated in the
present study were higher than those seen after either of these two
earlier vaccines, both in populations with endemic cholera and
without endemic cholera. For example, in Bangladesh the
internationally licensed oral B-subunit and whole cells elicited a
4-fold or greater increase in serum vibriocidal antibodies to O1
after the second dose in 43% of adults and in 30% of children, in
contrast to the figures of 53% and 80% of the corresponding age
groups in the present study done in Kolkata [7]. While definitive
conclusions about the comparative immunogenicity of these 3
vaccines would require direct, head-to-head comparisons, it is
interesting to note that the reformulated and re-standardized
version of the Vietnamese vaccine had an almost 40% increase in
the quantities of LPS antigen as compared to the earlier
Vietnamese vaccine.
Table 4. Frequency table of fold-increase of serum vibriocidal antibody titers to V. cholerae O1 Inaba and O139 from baseline and
14 days post-second dose among adult and children vaccinees
Fold increase in titers from baseline to 14 days after receipt of dose 2 among vaccinees
Adults
Baseline Titers
V. cholerae O1 V. cholerae O139*
#12481 6 3 2 6 4 1 2 8 2 5 6 5 1 2 #1 2 4 8 16 32 64 $128
#10 1 1 1 1
20 11
4 0 11132 6 1
80 2 1 2 3
1 6 0 3231 7 8 1
320 1 6 3 1 10 2
640 1 1 4 4
$1280 4 5 1 1
Children
Baseline Titers V. cholerae O1 V. cholerae O139*
#12481 6 3 2 6 4 1 2 8 2 5 6 5 1 2 $1024 #1 2 4 8 16 32 64 $128
#1 0 4 22122 1 2 2 2
2 0 1121 1 2 2 1
4 0 1 211 4 1 1
8 0 231 1 1 5 1
1 6 0 2212 4 3
320 3 1 6 4
640 1 2 3
$1280 2 2
*Titers to V. cholerae O139 were rounded up
doi:10.1371/journal.pone.0002323.t004
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the present study than those observed for the previous formulation
of the bivalent Vietnamese vaccine [3,6]. Although the vaccine vs.
placebo differences in the geometric mean fold rise were
statistically significant in both adults and children, the rise in
antibodies was substantially less compared to V. cholerae O1 Inaba
antibody titers. The baseline vibriocidal GMT to O139 of both
adults and children in our study was .100, higher than those seen
in Bangladesh [7,10] suggesting that our subjects may have been
primed by exposure to V. cholerae O139 or to other organisms with
cross-reacting O antigens. These higher baseline titers may have
contributed to the poorer anti-O139 vibriocidal responses in our
study. However even for those subjects with lower baseline titers
(#80), only 4 out of 11 adults and 12 out of 23 children
seroconverted. This lower vibriocidal response to V. cholerae O139
in the present study may have been due to differences in the assays
used. In an earlier study of the previous Vietnamese vaccine 2
indicator strains were used in the vibriocidal assays to the O139
serogroup [3]; in the present study we used a different indicator
strain. Although serum vibriocidal antibodies to O1 have been
regarded as an indirect immunologic correlate of vaccine
protection against this serogroup of cholera, the utility of results
from vibriocidal assays to O139 is still debated [10,14]. The
presence of a capsular polysaccharide in V. cholerae O139 may
interfere with the induction or detection of immune response and
detection of vibriocidal antibodies [10,14,15] . Whether the lower
vibriocidal responses to V. cholerae O139 in our study indicate that
the O139 component of this vaccine elicits poorer immunogenic
response, that the differences could have arisen due to differences
in the sensitivity of the vibriocidal assay used in our study, remains
to be seen and might only be resolved by vaccine efficacy studies.
A community-based, randomized, placebo-controlled efficacy trial
of a 2-dose regimen of the reformulated Vietnamese oral cholera
vaccine is currently underway in approximately 70,000 adults and
children in Kolkata. If the vaccine is found safe and protective, this
could pave the way for the wide use of this vaccine in the control of
cholera worldwide.
Supporting Information
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0002323.s001 (0.24 MB
DOC)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0002323.s002 (0.05 MB
DOC)
Acknowledgments
We are grateful to Dr Nguyen Thu Van, Dr Roger Glass, Dr Ann-Mari
Svennerholm and Ms Deok Ryun Kim.
Author Contributions
Conceived and designed the experiments: Lv JD JC DS AL DM. Analyzed
the data: JC AL SS. Contributed reagents/materials/analysis tools: JH RC
SH SA. Wrote the paper: AL. Other: Assured quality control of the
reformulated vaccine: JH. Supervised the conduct of the study: Lv DS.
Monitored and supervised the study implementation: AL. Implemented the
study: DM. Supervised data management: BM. Assured quality control of
the reformulated vaccine: RC. Performed the O1 assay: SH. Developed
the data management system: SS. Performed the O139 assay: SA. Assured
quality control of the reformulated vaccine: RR. Provided over-all
supervision of study implementation: SB. Provided assistance in study
implementation: SK.
References
1. (2002) World Health Organization Global Task Force on Cholera Control.
Cholera Vaccines: A new public health tool? Report of a WHO meeting, 10–11
December Geneva, Switzerland: World Health Organization.
2. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, et al. (1997) Field trial of a
locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349: 231–235.
3. Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, et al. (2002) Investigations into
the safety and immunogenicity of a killed oral cholera vaccine developed in Viet
Nam. Bull World Health Organ 80: 2–8.
4. Thiem VD, Deen JL, von Seidlein L, Canh do G, Anh DD, et al. (2006) Long-
term effectiveness against cholera of oral killed whole-cell vaccine produced in
Vietnam. Vaccine 24: 4297–4303.
5. Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, et al. (2003)
Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam.
J Health Popul Nutr 21: 304–308.
6. Anh DD, Canh do G, Lopez AL, Thiem VD, Long PT, et al. (2007) Safety and
immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral
cholera vaccine in adults. Vaccine 25: 1149–1155.
7. Clemens JD, Stanton BF, Chakraborty J, Sack DA, Khan MR, et al. (1987) B
subunit-whole cell and whole cell-only oral vaccines against cholera: studies on
reactogenicity and immunogenicity. J Infect Dis 155: 79–85.
8. Jertborn M, Svennerholm AM, Holmgren J (1986) Saliva, breast milk, and
serum antibody responses as indirect measures of intestinal immunity after oral
cholera vaccination or natural disease. J Clin Microbiol 24: 203–209.
9. Attridge SR, Johansson C, Trach DD, Qadri F, Svennerholm AM (2002)
Sensitive microplate assay for detection of bactericidal antibodies to Vibrio
cholerae O139. Clin Diagn Lab Immunol 9: 383–387.
10. Qadri F, Svennerholm AM, Shamsuzzaman S, Bhuiyan TR, Harris JB, et al.
(2005) Reduction in capsular content and enhanced bacterial susceptibility to
serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic
in Bangladesh. Infect Immun 73: 6577–6583.
11. Rao MR, Blackwelder WC, Troendle JF, Naficy AB, Clemens JD (2002) Sample
size determination for phase II studies of new vaccines. Vaccine 20: 3364–3369.
12. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, et al. (1993) Safety,
immunogenicity, and excretion pattern of single-dose live oral cholera vaccine
CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect
Immun 61: 3994–3997.
13. Taylor DN, Cardenas V, Perez J, Puga R, Svennerholm AM (1999) Safety,
immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/
rCTB) cholera vaccine in Peruvian adults and children. Am J Trop Med Hyg 61:
869–873.
14. Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, et al. (1997)
Vibriocidal antibody responses in North American volunteers exposed to wild-
type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.
Clin Diagn Lab Immunol 4: 264–269.
15. Qadri F, Mohi G, Hossain J, Azim T, Khan AM, et al. (1995) Comparison of the
vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal
with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab
Immunol 2: 685–688.
Oral Cholera Vaccine
PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2323